Credit Agricole S A Sells 17,962 Shares of Moderna, Inc. $MRNA

Key Points

• Credit Agricole S A reduced its stake in Moderna, selling 17,962 shares, which is a 5.2% decrease, leaving it with 324,710 shares valued at approximately $9.21 million.
• Analysts have a consensus rating of "Hold" for Moderna, with an average price target of $43.59, while the stock's recent trading range has been between $23.15 and $86.80.
• Moderna reported a quarterly earnings loss of ($2.13) EPS, which exceeded analysts' estimates, with revenue of $142 million despite a 41.1% decline compared to the same period last year.

Credit Agricole S A lessened its stake in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 5.2% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 324,710 shares of the company's stock after selling 17,962 shares during the period. Credit Agricole S A owned 0.08% of Moderna worth $9,206,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also added to or reduced their stakes in the company. S Bank Fund Management Ltd bought a new stake in shares of Moderna in the 1st quarter valued at about $25,000. Costello Asset Management INC purchased a new stake in Moderna during the first quarter valued at approximately $30,000. Sentry Investment Management LLC acquired a new stake in Moderna in the first quarter valued at approximately $31,000. Deseret Mutual Benefit Administrators grew its holdings in Moderna by 53.3% in the first quarter. Deseret Mutual Benefit Administrators now owns 1,128 shares of the company's stock worth $32,000 after purchasing an additional 392 shares during the last quarter. Finally, Itau Unibanco Holding S.A. grew its holdings in Moderna by 51.2% in the fourth quarter. Itau Unibanco Holding S.A. now owns 1,013 shares of the company's stock worth $42,000 after purchasing an additional 343 shares during the last quarter. 75.33% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

MRNA has been the subject of several analyst reports. Morgan Stanley reiterated an "equal weight" rating and set a $32.00 price objective on shares of Moderna in a report on Friday, August 1st. JPMorgan Chase & Co. set a $26.00 target price on Moderna in a research report on Friday, August 1st. Royal Bank Of Canada lowered their price target on Moderna from $32.00 to $28.00 and set a "sector perform" rating for the company in a report on Friday, May 2nd. Evercore ISI set a $32.00 price target on Moderna in a research note on Friday, August 1st. Finally, Cowen assumed coverage on shares of Moderna in a report on Sunday, July 13th. They set a "hold" rating on the stock. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, sixteen have given a Hold rating and four have issued a Sell rating to the stock. According to data from MarketBeat, Moderna has an average rating of "Hold" and a consensus price target of $43.59.

Moderna Stock Performance

Moderna stock opened at $26.22 on Friday. The business's 50-day simple moving average is $29.17 and its two-hundred day simple moving average is $29.17. The company has a market cap of $10.20 billion, a PE ratio of -3.48 and a beta of 1.83. Moderna, Inc. has a fifty-two week low of $23.15 and a fifty-two week high of $86.80.

Moderna (NASDAQ:MRNA - Get Free Report) last announced its quarterly earnings data on Friday, August 1st. The company reported ($2.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.99) by $0.86. The firm had revenue of $142.00 million during the quarter, compared to analysts' expectations of $116.26 million. Moderna had a negative return on equity of 25.96% and a negative net margin of 94.31%.The company's revenue for the quarter was down 41.1% compared to the same quarter last year. During the same period last year, the business posted ($3.33) earnings per share. Moderna has set its FY 2025 guidance at EPS. As a group, analysts predict that Moderna, Inc. will post -9.61 EPS for the current fiscal year.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.